Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy – an ancillary study of the SAKK 09/10 randomized clinical trial-Reference-Cited by-同舟云学术

Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy – an ancillary study of the SAKK 09/10 randomized clinical trial

Published:2022-09 Issue:9 Volume:33 Page:950-958
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Dal Pra A.,Ghadjar P.,Hayoz S.,Liu V.Y.T.,Spratt D.E.,Thompson D.J.S.,Davicioni E.,Huang H.-C.,Zhao X.,Liu Y.,Schär C.,Gut P.,Plasswilm L.,Hölscher T.,Polat B.,Hildebrandt G.,Müller A.-C.,Pollack A.,Thalmann G.N.,Zwahlen D.,Aebersold D.M.

Funder

AstraZeneca

Decipher Biosciences

Astellas Pharma US

Veracyte

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference18 articles.

1. Salvage therapy for prostate cancer after radical prostatectomy;Zaorsky;Nat Rev Urol,2021

2. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy;Tendulkar;J Clin Oncol,2016